Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase I/II, First-In-Human Trial of SRA141 for the Treatment of Advanced Colorectal Cancer

Trial Profile

A Phase I/II, First-In-Human Trial of SRA141 for the Treatment of Advanced Colorectal Cancer

Status: Planning
Phase of Trial: Phase I/II

Latest Information Update: 28 Feb 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs SRA 141 (Primary)
  • Indications Colorectal cancer
  • Focus Adverse reactions; First in man
  • Sponsors Sierra Oncology
  • Most Recent Events

    • 28 Feb 2019 According to a Sierra Oncology media release, the company is currently evaluating the optimal timing to commence this trial.
    • 13 Nov 2018 According to a Sierra Oncology media release, the Investigational New Drug Application (IND) process for SRA141 with the FDA has been completed and the IND application for SRA141 has been accepted by the U.S. FDA.
    • 10 Aug 2018 According to a Sierra Oncology media release, Upon dosing of the first patient in the first Phase 1 clinical trial of SRA141, a milestone payment of $4.0 million will be due to Carna Biosciences, Inc. (Carna), the licensor of this asset.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top